Curio Wealth LLC Acquires 872 Shares of Merck & Co., Inc. $MRK

Curio Wealth LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 43,600.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 874 shares of the company’s stock after buying an additional 872 shares during the period. Curio Wealth LLC’s holdings in Merck & Co., Inc. were worth $69,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of MRK. Charles Schwab Investment Management Inc. grew its holdings in shares of Merck & Co., Inc. by 144.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock valued at $4,418,820,000 after acquiring an additional 29,104,112 shares in the last quarter. Nuveen LLC bought a new position in shares of Merck & Co., Inc. in the first quarter valued at approximately $991,553,000. Pacer Advisors Inc. grew its holdings in shares of Merck & Co., Inc. by 2,240.9% in the first quarter. Pacer Advisors Inc. now owns 5,286,801 shares of the company’s stock valued at $474,543,000 after acquiring an additional 5,060,959 shares in the last quarter. Amundi lifted its stake in Merck & Co., Inc. by 37.1% in the first quarter. Amundi now owns 13,077,716 shares of the company’s stock valued at $1,130,397,000 after purchasing an additional 3,542,036 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new position in Merck & Co., Inc. in the second quarter valued at approximately $258,267,000. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Up 0.4%

NYSE:MRK opened at $87.54 on Friday. The company has a market cap of $218.65 billion, a P/E ratio of 13.49, a P/E/G ratio of 0.96 and a beta of 0.37. The stock’s fifty day moving average price is $84.43 and its two-hundred day moving average price is $81.54. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $106.49. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.10. The firm had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Analyst Upgrades and Downgrades

MRK has been the topic of several research analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Wells Fargo & Company dropped their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Citigroup initiated coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 price objective on the stock. Finally, Morgan Stanley dropped their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $104.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.